Hematopoietic stem cells (HSCs) have immense therapeutic potential because of their ability for both self-renewal and multi-lineage differentiation to maintain hematopoietic homeostasis. This rare population of cells are characterized by the presence of the cell surface marker CD34, which is useful for their identification and isolation from the bone marrow and peripheral blood. In the […]
Cell and gene therapies represent an expanding category of transformative medicines with the potential to change the way we treat human diseases. Broadly, these novel therapies include both in vivo and ex vivo strategies to modify target cells. Ex vivo therapies that involve isolating cells from a patient (autologous) or a donor (allogeneic) and modifying […]
In the past decade, emerging therapeutic modalities like cell and gene therapies have opened up new treatment options for previously intractable diseases, changing the industry needs for primary tissues. While autologous therapies—which are created using a patient’s own cells—still dominate the field, many cell and gene developers are investing in allogeneic therapies that can be […]
Welcome to the second installment of our FAQ blog series! Today, we are looking at differences between CD34+ cells isolated from different tissue sources to provide a better understanding of this important cell population. Hematopoietic stem cells (HSCs) are an important and rare population of cells that reside in a specialized niche within the bone […]
What are Monocytes? Hematopoietic stem cells (HSCs), which reside in the bone marrow give rise to blood cells in a process called hematopoiesis. HSCs differentiate into the lymphoid and myeloid lineages, which further differentiate into mature blood cell types (Figure 1). Monocytes are large agranular leukocytes of the myeloid lineage comprising between 5% – 10% […]
